The 67th American Society of Hematology (ASH) Annual Meeting will be held in Orlando, Florida, USA, from December 6 to 9, 2025. Three studies from the Department of Hematology of the 920th Hospital have been accepted as poster presentations, marking a new milestone in the department’s innovative research in hematologic diseases.
The ASH Annual Meeting is widely recognized as the largest, most influential, and most comprehensive international academic event in hematology, covering both malignant and non-malignant blood disorders. Each year, it attracts more than 30,000 experts and scholars from around the world, with only about 5,000 highly innovative abstracts accepted for presentation.
Abstract ID: abs25-15392
Title: Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia First author: Shiqi Li Corresponding author: Sanbin Wang
This study evaluated the safety and efficacy of autologous CD19-directed CAR-T cell therapy in four patients with refractory primary immune thrombocytopenia (ITP). The treatment showed a favorable safety profile, with only mild cytokine release syndrome and no severe neurotoxicity. All patients experienced B-cell depletion. Three patients responded to therapy, including one who achieved a complete response.
The investigators also observed that the patient with suboptimal response to CAR-T experienced a marked platelet increase after receiving daratumumab, highlighting the crucial role of plasma cell clearance in the management of refractory ITP.
Abstract ID: abs25-12534
Title: An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients First author: Shiqi Li Corresponding author: Sanbin Wang
This study provided an updated analysis of the safety and efficacy of GPRC5D-targeted CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (R/R MM). The results support GPRC5D as a promising and safe immunotherapy target in MM.
For patients with GPRC5D-positive R/R MM—especially those who are refractory to BCMA-directed CAR-T therapy—GPRC5D CAR-T offers a highly promising therapeutic option and represents an important potential strategy after BCMA failure.
Abstract ID: abs25-9739
Title: Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study First author: Xiaoping Li Corresponding author: Sanbin Wang
This prospective, multicenter, single-arm clinical study, led by the Department of Hematology of the 920th Hospital and conducted in collaboration with several centers across China, aims to evaluate the application of a fludarabine, cyclophosphamide, and melphalan (FCM) conditioning regimen in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia.
The study focuses on the efficacy and safety of the FCM regimen in this setting and is expected to provide important clinical evidence to optimize conditioning strategies for transplant in severe aplastic anemia.
Department Overview
The 920th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army is a military hospital with a long history, founded in wartime. The origins of its hematology services date back to the 1960s. After decades of development under successive academic leaders, an independent Department of Hematology was formally established in 2013.
The department now holds a leading position in Yunnan Province. It is recognized as a provincial key clinical specialty and one of the first key medical disciplines within the Joint Logistics Support Force. It currently serves as the chair unit of the Hematology Branch of the Yunnan Medical Association and as a vice-chair unit of the Hematology Physicians Branch of the Yunnan Medical Doctor Association.
The department runs two inpatient wards with more than 100 beds, including 14 Class 100 laminar-flow isolation rooms. It is equipped with specialized facilities such as Class 100 laminar-flow hoods, cell separators, flow cytometers, red blood cell lifespan analyzers, high-speed centrifuges, telemetry ECG monitoring systems, air disinfection units, microscopic imaging systems, and ultra–low-temperature freezers.
On average, the department handles over 10,000 outpatient visits and more than 2,000 discharges per year, with complex and critically ill cases accounting for over 70%. Its core strengths lie in hematopoietic stem cell transplantation and immune cell therapy. The annual transplant volume ranks first in Yunnan Province and third within the entire PLA system. The department was the first in Yunnan to carry out a full range of CAR-T projects and gene therapy programs.
Expert Profile
Professor Sanbin Wang Department of Hematology, 920th Hospital of the Joint Logistics Support Force of the PLA
Professor Wang is a chief physician and doctoral supervisor at the 920th Hospital. He serves as: Member of the Hematology Physicians Branch of the Chinese Medical Doctor Association; Member of the Hematology Branch of the Chinese Society of Integrative Medicine; Member of the Cellular Therapy Group of the Hematologic Oncology Committee of the Chinese Anti-Cancer Association; Member of the Hematology Professional Committee of the Integrative Medicine Physicians Branch of the Chinese Medical Doctor Association; Member of the Hematology Committee of the PLA Medical Science and Technology Commission; Chair of the Hematology Branch of the Yunnan Medical Association; Vice Chair of the Hematology Physicians Branch of the Yunnan Medical Doctor Association.
He has received a First Prize of the Science and Technology Award from the Chinese Association for Laboratory Animal Sciences, two Third Prizes for Scientific and Technological Progress in Yunnan Province, and one First Prize in the Kunming Science and Technology Program. He has led a major provincial project in biomedicine funded by the Yunnan Provincial Department of Science and Technology.
As first or corresponding author, he has published more than 40 academic papers in journals including Journal of Clinical Oncology (JCO) and Clinical Cancer Research (CCR).
His main clinical and research interests include:
- Hematopoietic stem cell transplantation
- Management of HIV-related hematologic diseases
- “Off-the-shelf” (universal) CAR-T therapy for hematologic malignancies
- Gene therapy for transfusion-dependent β-thalassemia
